4.7 Article

Increased cerebral functional connectivity in ALS A resting-state magnetoencephalography study

期刊

NEUROLOGY
卷 90, 期 16, 页码 E1418-E1424

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000005333

关键词

-

资金

  1. Medical Research Council UK MEG Partnership Grant [MR/K005464/1]
  2. National Institute for Health Research (Oxford Biomedical Research Centre based at Oxford University Hospitals Trust)
  3. Wellcome Trust [104369/Z/14/Z]
  4. Research Councils UK Digital Economy Programme (Centre for Doctoral Training in Healthcare Innovation) [EP/G036861/1]
  5. Wellcome Trust Senior Investigator Award [104571/Z/14/Z]
  6. Muscular Dystrophy Association [4365, 172123]
  7. ALS Association
  8. Kimmelman Estate
  9. ALS Recovery Fund
  10. Medical Research Council
  11. Motor Neurone Disease Association Lady Edith Wolfson Senior Clinical Fellowship [MR/K01014X/1]
  12. MRC [MR/L023784/2, MR/K01014X/1] Funding Source: UKRI
  13. Wellcome Trust [104369/Z/14/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

Objective We sought to assess cortical function in amyotrophic lateral sclerosis (ALS) using noninvasive neural signal recording. Methods Resting-state magnetoencephalography was used to measure power fluctuations in neuronal oscillations from distributed cortical parcels in 24 patients with ALS and 24 healthy controls. A further 9 patients with primary lateral sclerosis and a group of 15 asymptomatic carriers of genetic mutations associated with ALS were also studied. Results Increased functional connectivity, particularly from the posterior cingulate cortex, was demonstrated in both patient groups compared to healthy controls. Directionally similar patterns were also evident in the asymptomatic genetic mutation carrier group. Conclusion Increased cortical functional connectivity elevation is a quantitative marker that reflects ALS pathology across its clinical spectrum, and may develop during the presymptomatic period. The amelioration of pathologic magnetoencephalography signals might be a marker sensitive enough to provide proof-of-principle in the development of future neuroprotective therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Clinical Neurology

Teaching Video NeuroImages: Acute Adie syndrome

Benjamin R. Wakerley, Mei Hong Tan, Martin R. Turner

NEUROLOGY (2023)

Article Clinical Neurology

Atypical TDP-43 protein expression in an ALS pedigree carrying a p.Y374X truncation mutation in TARDBP

Johnathan Cooper-Knock, Thomas H. Julian, Emily Feneberg, J. Robin Highley, Maurice Sidra, Martin R. Turner, Kevin Talbot, Olaf Ansorge, Scott P. Allen, Tobias Moll, Tatyana Shelkovnikova, Lydia Castelli, Guillaume M. Hautbergue, Christopher Hewitt, Janine Kirby, Stephen B. Wharton, Richard J. Mead, Pamela J. Shaw

Summary: We describe a multi-generational pedigree of amyotrophic lateral sclerosis (ALS) with an autosomal dominant, fully penetrant mutation in the TDP-43 gene. The hallmark pathology of ALS is the mislocalization of TDP-43 and the formation of insoluble TDP-43-positive neuronal cytoplasmic inclusions. While the lower motor neurons showed typical TDP-43 pathology, the motor cortex did not show classical TDP-43-positive inclusions. Despite reduced overall TDP-43 protein expression, the mutated allele was transcribed and translated in patient fibroblasts and motor cortex tissue. Furthermore, the motor cortex tissue carrying the mutation showed atypical TDP-43 protein species but not typical C-terminal fragments. Our findings suggest that the p.Y374X mutation is responsible for a monogenic, fully penetrant form of ALS and expands the molecular phenotypes associated with TDP-43 mutations and ALS.

BRAIN PATHOLOGY (2023)

Article Clinical Neurology

Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12

Carolyn A. Young, John Ealing, Christopher J. McDermott, Tim L. Williams, Ammar Al-Chalabi, Tahir Majeed, Kevin Talbot, Timothy Harrower, Christina Faull, Andrea Malaspina, Joe Annadale, Roger J. Mills, Alan Tennant

Summary: The aim of this study was to investigate whether the WHODAS 2.0 can provide interval level measurement of disability in ALS, allowing parametric analyses. The results showed that the WHODAS 2.0 can be used as a brief patient reported outcome measure to assess disability in ALS and can be used for surveillance of at risk populations.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Neurosciences

Mapping Interictal activity in epilepsy using a hidden Markov model: A magnetoencephalography study

Zelekha A. Seedat, Lukas Rier, Lauren E. Gascoyne, Harry Cook, Mark W. Woolrich, Andrew J. Quinn, Timothy P. L. Roberts, Paul L. Furlong, Caren Armstrong, Kelly St Pier, Karen J. Mullinger, Eric D. Marsh, Matthew J. Brookes, William Gaetz

Summary: Epilepsy is a highly heterogeneous neurological disorder. In this study, a hidden Markov model (HMM) was used to create a statistical model of interictal brain activity in pediatric patients with epilepsy. The HMM showed comparable performance to the current method and provided additional information about the relationship between epileptogenic areas. It offers personalized results and can be used in surgical decision-making.

HUMAN BRAIN MAPPING (2023)

Article Clinical Neurology

Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months

C. A. Young, J. Ealing, C. J. McDermott, T. L. Williams, A. Al-Chalabi, T. Majeed, K. Talbot, T. Harrower, C. Faull, A. Malaspina, J. Annadale, R. J. Mills, A. Tennant

Summary: This study reveals that the prevalence of depression in ALS patients is close to a quarter, with most patients belonging to a single trajectory group. Estimates based on screening for current depressive symptoms underestimate the actual prevalence of depression.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning

Hugo M. De Oliveira, Arunachalam Soma, Mark R. Baker, Martin R. Turner, Kevin Talbot, Timothy L. Williams

Summary: There is considerable variation in the practice of genetic testing for patients with sporadic motor neurone disease/amyotrophic lateral sclerosis (MND/ALS) and asymptomatic at-risk relatives in specialized care centers in the UK. Many healthcare professionals feel uncomfortable discussing genetic testing with MND/ALS patients and believe that routine genetic testing is not necessary for all patients with apparently sporadic disease. There are concerns regarding testing asymptomatic at-risk individuals and the majority view is that clinical genetics services should play a role in supporting genetic testing in MND/ALS, especially in asymptomatic individuals at risk of carrying pathogenic variants.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Neurosciences

Multiple and Dissociable Effects of Sensory History on Working-Memory Performance

Jasper E. Hajonides, Freek van Ede, Mark G. Stokes, Anna C. Nobre, Nicholas E. Myers

Summary: Behavioral reports of sensory information are influenced by stimulus history, with both attractive and repulsive biases observed. However, the underlying mechanisms in the human brain are not well understood. In this study, through a working-memory task and analysis of magnetoencephalographic (MEG) data, it was found that neural representations during stimulus encoding were biased away from the previous orientation, despite opposite effects on behavior. These results suggest that repulsive biases occur in sensory processing and can be overridden at postperceptual stages to result in attractive biases in behavior.

JOURNAL OF NEUROSCIENCE (2023)

Review Neurosciences

Attention in flux

Anna C. Nobre, Freek van Ede

Summary: Selective attention is an essential cognitive function that involves predicting, prioritizing, selecting, routing, integrating, and preparing signals to guide adaptive behavior. This review focuses on the impact of timing on attention and highlights the challenges posed by the timing of neural processing and psychological functions, the opportunities provided by temporal structures in the environment, and the insights gained from tracking the time courses of neural and behavioral modulations using continuous measures.

NEURON (2023)

Article Biology

Spatiotemporal organisation of human sensorimotor beta burst activity

Catharina Zich, Andrew J. Quinn, James J. Bonaiuto, George O'Neill, Lydia C. Mardell, Nick S. Ward, Sven Bestmann

Summary: Beta oscillations in the human sensorimotor cortex exhibit burst activity in intermittent periods of high-power, and these bursts are associated with various sensory and motor processes. The precise spatiotemporal structure of beta burst activity remains unclear, but it is suggested that they play a role in information coding and communication. In this study, using magnetoencephalography recordings, we observed that burst activity in the sensorimotor cortex occurs in planar spatiotemporal wave-like patterns along specific anatomical gradients. Furthermore, we found distinct anatomical, spectral, and spatiotemporal characteristics for the two directions of propagation.
Article Medicine, Research & Experimental

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice

Anna J. Kordala, Jessica Stoodley, Nina Ahlskog, Muhammad Hanifi, Antonio Garcia Guerra, Amarjit Bhomra, Wooi Fang Lim, Lyndsay M. Murray, Kevin Talbot, Suzan M. Hammond, Matthew J. A. Wood, Carlo Rinaldi

Summary: Spinal muscular atrophy (SMA) is an important genetic cause of infant mortality. The discovery of PRMT inhibitor MS023 shows promising potential for treating SMA and improving the disease phenotype, especially when combined with nusinersen. Further clinical investigation of PRMT inhibition as a standalone or add-on therapy for SMA is warranted.

EMBO MOLECULAR MEDICINE (2023)

Article Clinical Neurology

Aberrant dynein function promotes TDP-43 aggregation and upregulation of p62 in male mice harboring transgenic human TDP-43

Eleni Christoforidou, Fabio A. Simoes, David Gordon, Kevin Talbot, Majid Hafezparast

Summary: This study examined the intracellular motor neuron pathology of mice with a combination of defective dynein and a TDP-43 mutation. The results showed upregulation of p62 and aggregation of TDP-43, partially recapitulating the human disease. These findings provide new insights into the relationship between dynein and TDP-43 and could be useful for further research on the TDP-43 pathology in ALS.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2023)

Article Clinical Neurology

Primary care blood tests show lipid profile changes in pre-symptomatic amyotrophic lateral sclerosis

Alexander G. Thompson, Rachael Marsden, Kevin Talbot, Martin R. Turner

Summary: Using routine health screening blood test data, this study found distinct pre-symptomatic biphasic blood cholesterol trajectories in individuals who later developed amyotrophic lateral sclerosis. The findings suggest that metabolic alterations may occur prior to the onset of motor symptoms in this disease. These findings provide further evidence for the importance of monitoring blood cholesterol levels for early detection and potential preventative therapy in amyotrophic lateral sclerosis.

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

Limited value of serum neurofilament light chain in diagnosing amyotrophic lateral sclerosis

Jennifer C. Davies, Thanuja Dharmadasa, Alexander G. Thompson, Evan C. Edmond, Katie Yoganathan, Jiali Gao, Kevin Talbot, Martin R. Turner

Summary: A reliable biomarker for diagnosing amyotrophic lateral sclerosis (ALS) across different clinical conditions is necessary. Neurofilament light chain levels are correlated with the progression of disability in ALS patients. Previous studies have only compared neurofilament light chain levels in ALS patients with healthy individuals or controls with diagnoses distinct from ALS. In this study, neurofilament light chain levels were measured in ALS patients referred to a specialized clinic, and it was found that neurofilament light chain levels can confirm ALS diagnosis but have limited ability to exclude alternative diagnoses. The current importance of neurofilament light chain is its potential use in stratifying ALS patients by disease activity and as a biomarker in therapeutic trials.

BRAIN COMMUNICATIONS (2023)

暂无数据